[Detection of KRAS mutations: evolution or revolution for the pathologists?]

Ann Pathol. 2008 Sep;28(4):261-2. doi: 10.1016/S0242-6498(08)00273-3.
[Article in French]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology
  • Cetuximab
  • ErbB Receptors / immunology
  • Female
  • Humans
  • Mutation*
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins p21(ras)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Trastuzumab
  • ras Proteins / genetics*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • ErbB Receptors
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • Trastuzumab
  • Cetuximab